On July 13, 2026, Enlivex Ltd. announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy. The designation is intended for treating age-related symptomatic knee osteoarthritis in patients aged 64 and older. Enlivex is a biotechnology company developing immunotherapies.
